Pfizer advances an abuse-deterrent pain med; Chinese-born scientists return home for biotech;

@FierceBiotech: Eisai wins an early FDA nod for its self-described cancer blockbuster. Report | Follow @FierceBiotech

@JohnCFierce: Biotech boom drives blockbuster VC investments in Boston, San Francisco. Story | Follow @JohnCFierce

@DamianFierce: Eisai exec told WSJ yesterday that lenvatinib approval was "imminent." Well. FDA announcement | Follow @DamianFierce

> The FDA has accepted Pfizer's ($PFE) application for ALO-02, an abuse-deterrent painkiller that combines oxycodone and naltrexone. The company didn't disclose when it expects to get a final ruling from the agency. More

> A generation of Chinese scientists who once left the country for jobs in western pharma are returning home, lured by the nascent biotech ecosystem there, Reuters reports. Story

Medical Device News

@FierceMedDev: J&J joins forces with JDRF for type 1 diabetes Dx. FierceDiagnostics story | Follow @FierceMedDev

@VarunSaxena2: ICYMI yesterday: NIH discusses 'precision medicine' genomics initiative and how to build a million-person research cohort. Item | Follow @VarunSaxena2

@EmilyWFierce: Better training for pediatricians could help increase use of IUDs in teenage girls. Story from The Atlantic | Follow @EmilyWFierce

> USAID backs wearable tech initiative for Ebola from Scripps. Article

> Disposable insulin device maker Valeritas files to raise up to $90M in an IPO. Report

Pharma News

@FiercePharma: UPDATED: Valeant, Shire prep Salix bids. Article | Follow @FiercePharma

@CarlyHFierce: ICYMI yesterday: Teva 'likely' violated FCPA, local laws in Russia, Latin America and elsewhere. Report | Follow @CarlyHFierce

> Activists ready to fight for Ariad CEO's ouster: CNBC. More

> Gilead strikes Sovaldi price deal in Germany as it picks up speed in EU. Article

> England's price watchdog writes off Celgene's Imnovid in final guidance. Story